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Summary
We analyzed the effect of oral administration of cyclosporine-methylprednisone 
(CsA-MP) and sirolimus (SRL) on the lipid pattern of kidney-transplanted rats 
after a 7-day survival. A significant increase in plasma cholesterol in CsA-MP 
group (control: 26 ± 3 mg/dl vs. 59 ± 8 mg/dl, P < 0.05) and in triglyceride 
levels in SRL group (control: 53 ± 4 mg/dl vs. 114 ± 3 mg/dl, P < 0.05), was 
shown. Kidney microsomal membranes from both treated groups showed that 
cholesterol and triglyceride values and the relative percentage of arachidonic 
acid in the total amount of n-6 fatty acids decreased. A diminution of linoleic 
acid occurred in testis (control: 9.4 ± 0.1 mg/dl vs. CsA-MP: 6.0 ± 0.3 mg/dl 
and vs. SRL: 6.8 ± 0.2 mg/dl, P < 0.05), liver (control: 17.7 ± 0.6 mg/dl vs. 
CsA-MP: 15.1 ± 0.6 mg/dl and SRL: 13.5 ± 0.8 mg/dl, P < 0.05) and erythro­
cyte membranes (controls 1.7 ± 0.1% vs. CsA-MP: 10.6 ± 0.2% and SRL: 
10.0 ± 0.4%, P < 0.01). The immunosuppressive therapies improved the rejec­
tion rate of the graft, fact that was remarkable in the SRL-treated group. How­
ever, lipid abnormalities still remain in spite of immunosuppressive therapies. 
(150).
Introduction
Dyslipidemias represent a group of disorders that compro­
mise a variety of lipid abnormalities. These lipid abnormal­
ities are common in patients with renal disease and remain 
after a successful renal transplantation [1-3]. Moreover, 
these disorders are key factors in the development of chro­
nic allograft dysfunction, and they are independent factors 
associated with cardiovascular complications [4].
Although some early studies focused mainly on 
increased serum cholesterol, recent data emphasized that 
a high triglyceride concentration predicts coronary heart 
disease independent of other known factors [5-7].
Essential fatty acids (EFA) are specific polyunsaturated 
fatty acids (PUFA) for which all animals have an obliga­
tory dietary requirement [8]. EFA of the n-6 and n-3 
families, after their release from their membrane 
phospholipid reservoirs, become eicosanoids, which are 
important as autacoids and second messengers in signal 
transduction of endocrine and other kinds of stimuli [9]. 
EFA deficiency results in biochemical disorders involved 
in the etiology of coronary vascular diseases [10].
Patients with chronic renal failure exhibit plasma fatty 
acid patterns which are indicative of EFA deficiency. 
Thus, plasma PUFA decreased and saturated fatty acids 
increased in both plasma and red blood membranes, 
altering the fluidity of the latter [5,11,12]. Moreover, 
d’Apice et al. [13] and Lawen et al. [14] showed that kid­
neys from EFA deficient rats transplanted to normal 
recipients developed a marked increase in renal interstitial 
cells and a reduction in allograft survival.
On the contrary, qualitatively and quantitatively, post­
transplant secondary dyslipidemias arise as a consequence 
of the immunosuppressive treatment used to abolish 
rejection [15]. The extent to which immunosuppressants, 
directly or indirectly, influence the serum and mem­
branes lipid pattern in renal recipients is still unclear. 
Post-transplantation steroid therapy in humans has been 
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correlated with hyperlipidemia which promotes athero­
sclerosis often prevalent in the hemodialysis population 
before transplantation [1, 16]. The use of cyclosporine A 
(CsA) in immunosuppression protocols diminished the 
incidence of acute rejection episodes without the amelior­
ation of the atherogenic profile [17]. However, the role of 
CsA on the lipid pattern is not clear as most patients 
received a combined therapy with prednisone. In previous 
experiments the influence of both drugs on the biosynthe­
sis of PUFA, serum lipids as well as the fatty acid compo­
sition of different tissues has been established in normal 
rats in which the drugs could be evaluated independently 
[18]. The dual therapy with CsA-methylprednisone 
(CsA-MP) increased cholesterol and triglyceride plasma 
levels and depressed PUFA biosynthesis in liver at the 
level of both A6 and A5 desaturation activities. CsA 
monotherapy produced a significant depression in plasma 
triglycerides while PUFA biosynthesis remained under the 
same values obtained for the controls [18].
Cyclosporine A inhibits T-cell activation by blocking 
the transcription of cytokine genes, including those of 
IL-2 and IL-4 [19]. Sirolimus (SRL), a novel immunosup­
pressant, prolongs allograft survival in animal models, 
inhibiting cytokine receptor-mediated signal transduction 
instead of a direct inhibition of IL-2 gene transcription 
[20]. Experimental transplant models and initial clinical 
data suggest that SRL in combination with CsA reduce 
the rate of acute rejection episode, and facilitate cortico­
steroid withdrawal [21,22]. However, SRL seemed to 
enhance the hypercholesterolemic and hypertriglyceridemic 
effects of CsA [21-23].
To elucidate the influence of immunosuppressive ther­
apy in producing dyslipidemias after a 7-day survival, we 
studied serum and membrane lipids of many tissues in 
kidney transplanted rats that had been treated with CsA- 
MP or the monotherapy with SRL.
Materials and Methods
Animals
Forty-two outbred male Wistar rats, weighing 280-350 g 
were used as donors (n = 18), recipients (n = 18) and 
controls (n = 6). Animals were allowed free access to 
water and standard laboratory chow ad libitum. All ani­
mal experiments were performed according to the guide­
lines set by the National Institutes of Health (NIH 
publication No. 86-23, revised 1985).
Kidney transplantation and animal treatments
Recipients were divided in three groups of six recipients 
each. CsA-MP group was given a daily oral dose of CsA 
(Sandimmune; Novartis Pharma LTD, Basel, Switzerland), 
5 mg/kg body weight, in combination with MP, 1 mg/kg 
body weight; SRL group was administered a daily oral 
dose of SRL (Rapamycin; Rapamune, Wyeth-Ayerst 
Laboratories, St David’s, PA, USA), 3 mg/kg body weight; 
recipients without inmunosuppressive therapy were con­
sidered as TXR group. Six nontransplanted rats without 
immunosuppressive therapy served as control group. 
Doses of immunosuppressants are those required to pre­
vent kidney rejection in the rat [22,24,25].
Blood samples were collected from the tail vein in each 
recipient (before transplantation) and in controls to 
obtain the baseline data, and at the end of the experiment 
by draining off, for cholesterol, triglyceride, creatinine 
and urea determinations. Animals were fasted 24 h prior 
to sample collection, surgery procedure, and killing. Rat 
renal transplants were performed as previously described 
[26]. Briefly, in anesthetized donor rats, the left kidney 
[transplanted kidney (TK)] was carefully removed, 
weighed and stored in cold Ringer lactate solution. The 
donor’s right kidney (DK) was removed, weighed and 
homogenized in cold homogenizing solution (HS, 1:3 
w/v) which consisted of: 0.25 m sucrose, 62 mM phos­
phate buffer (pH 7.0), 0.15 m KC1, 5 mM MgCl2 and 
100 llm EDTA. In the recipient right nephrectomy was 
performed and the excised kidney (EK) was weighed and 
homogenized in HS. The donor’s left kidney was trans­
planted into the abdominal cavity of the recipient. The 
ureter was sutured by an end-to-end anastomosis. The 
native right kidney (NK) was left in situ. The average 
total ischemic time was 90 ± 15 min. Immediately after 
surgery rats were allow free access to water and standard 
laboratory chow ad libitum and they were treated with 
buprinorphine (0.04 mg/kg body weight) as analgesic 
therapy every 12 h until the third postoperative day. The 
animals were killed on the seventh postoperative day.
Isolation of kidney, liver and testis microsomes and 
erythrocyte membranes
One week after surgery rats were killed by decapitation. 
Blood was drained off and collected into test tubes con­
taining an anticoagulant EDTA solution (Wiener Lab., 
Rosario, Argentina). Liver, kidney and testis were excised, 
weighed, and homogenized as indicated before. The 
microsomal fraction was separated by differential cold 
(4 °C) centrifugation at 10 000 g for 20 min and ultra­
centrifugation at 45 000 g for 1 h and 40 min.
Whole blood was centrifuged, plasma was immediately 
separated, and packed red blood cells were washed four 
times, at 4 °C, with a buffered solution containing NaCl 
(140 mM), KC1 (5 mM), NaHSO4 (1 mM), Tris buffer 
(10 mM), pH 7.4. After agitation they were kept at 4 °C 
for 10 min, and centrifuged at 16 000 g for 15 min. This 
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procedure was carried out twice, leaving a substantially 
hemoglobin-free pellet of erythrocyte membranes, which 
were resuspended in a small amount of supernatant, and 
stored (-70 °C) until assayed.
Lipid extraction and analysis
Lipids from erythrocyte membranes and liver, kidney and 
testis microsomes were extracted with chloroform-meth- 
anol (2:1 v/v). After conversion of the fatty acids to their 
corresponding methyl esters they were analyzed using a 
Hewlett-Packard Model 5840-A gas-liquid chromatograph 
(Hewlett-Packard, Palo Alto, CA, USA) equipped with a 
flame-ionization detector. An aliquot from the organic 
phase of kidney microsome extraction was separated to 
determine phospholipid and neutral lipid content through 
flame ionization detector (FID) of an Iatroscan apparatus 
model TH 10 (Latron Laboratories, Tokyo, Japan). Lipids 
were separated on previously activated chromarods type 
S-III, under a double-development system. The first 
mobile phase was hexane-benzene (70:30 v/v) whereas 
the second was benzene-chloroform-formic acid (70:25:2 
v/v/v). Lipidie species were quantified by comparison 
with known amounts of pure standards run under the 
same conditions. The signals from the FID were registered 
on a Hewlett-Packard model HP-3396 A integrator.
Chemical determinations
To measure plasma cholesterol and triglyceride levels, 
blood was collected by puncture of the tail vein 1 week 
before surgery and at the time of killing. Both variables 
were assayed by commercial enzymatic methods (Sera-Pak 
Bayer Corporation, Tarrytown, NY, USA). In the same 
blood samples creatinine and urea plasma levels were also 
determined by enzymatic methods (Bio Systems, S. A. Bar­
celona, Spain; Wiener Lab., Rosario, Argentina, respect­
ively).
Histopathologic analysis
Histopathologic analysis was performed on graft and native 
kidney removed on seventh postoperative day. Biopsies 
were fixed with Bouin’s solution and embedded in paraffin. 
For this routine 5-pm (paraffin) sections were stained with 
hematoxylin-eosin and periodic acid-Schiff standard pro­
cedures. Samples were studied by light microscopy at 40x.
Statistical analysis
Results were tested statistically using either the Student 
t-test compared with the respective control, or the 
one-way anova as appropriate.
Results
Plasma cholesterol, triglyceride, creatinine 
and urea levels
Cholesterol and triglyceride levels in nontransplanted (con­
trol) and transplanted rats as well as in the transplanted 
ones treated with CsA-MP and SRL are shown in Table 1. 
A significant increase was noted in cholesterol in TXR 
group compared with control. A further enhancement in 
sterol was shown in transplanted rats under CsA-MP treat­
ment. A slight increase was observed in the SRL group, 
compared with the data obtained before the surgery. Tri­
glyceride values showed no changes in either transplanted 
nontreated rats or CsA-MP-treated animals compared 
with the control. A twofold increase in triglycerides values 
was shown in the SRL group compared with either the 
control or those rats without immunosuppressant therapy.
Creatinine plasma levels increased significantly in the 
TXR group compared with nontransplanted rats 
(Table 1). In the animals with immunosuppressive ther­
apy the values of creatinine were similar to those of con­
trols. Urea plasma levels showed no significant changes 
among the groups.
Membrane lipids
Fatty acid profile of plasma, erythrocyte membrane, and 
liver, testis and kidney microsomal membranes.
The fatty acid composition of kidney microsomal total 
lipids of CsA-MP and SRL groups is shown in Figs 1 and 
2, respectively. No changes were seen in the relative per­
centages of the different fatty acids between the donor’s 
remaining kidney (DK) and the recipient’s EK when com­
pared using Student t-test. A decrease in the relative per­
centage of arachidonic acid (20:4 n-6) was shown after 
comparing the fatty acid composition of controls versus 
NK and TK of the rats treated either with CsA-MP or 
SRL. These alterations were more pronounced in the graft 
than in native kidneys. In both groups (treated with CsA- 
MP and treated with SRL) an increase in 18:1 n-7 acid
Table 1. Cholesterol, triglycerides, urea and creatinine levels.
Pretransplant TXR CsA-MP SRL
values (n = 24) (n = 6) (n = 6) (n = 6)
Cholesterol 26 ± 3 39 ± 2*f 59 ± 8* 35 ± 4
Triglycerides 53 ± 4 57 ± 5 51 ± 4 114 ± 3*f
Urea 40 ± 4 49 ± 3 50 ± 4 54 ± 4
Creatinine 1.5 ± 0.05 2.4 ± 0.2* 1.2 ± 0.05 1.4 ± 0.08
Data are the mean ± SEM expressed as mg/dl.
^Significantly different from pretransplant values at P < 0.05. 
■^Significantly different from transplanted rats without immunosup­
pressive therapy at P < 0.05 using anova.
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Figure 1 Fatty acid composition of 
kidney microsomal total lipids from control 
and transplanted kidneys of recipients. 
Fatty acids are identified by: number of 
carbon atoms in the chain is given first, 
value following the double point repre­
sents number of double bonds (zero 
means saturated fatty acids); number 
following 'n' indicates the position of the 
last double bond counting the double 
bond from the terminal methyl group. 
Data are the mean of six determinations 
±SEM expressed as % of total fatty acids. 
‘Significantly different from control at 
P < 0.05. §Significantly different from 
transplanted rats without immunosuppres­
sive therapy at P < 0.05 using anova.
Figure 2 Fatty acid composition of kid­
ney microsomal total lipids from control 
and native kidneys of recipients. Identifica­
tion of fatty acids as in Fig. 1. Data are 
the mean of six determinations ±SEM 
expressed as % of total fatty acids. ‘Signi­
ficantly different from control at P < 0.05. 
§Significantly different from transplanted 
rats without immunosuppressive therapy 
at P < 0.05 using anova.
was observed. In the CsA-MP group an enhancement of 
18:1 n-9 and in 22:5 n-3 was observed in TK and NK 
compared with control (18:1 n-9: mean ± SEM were 
7.4 ± 0.2% in control group vs. 9.7 ± 0.4% TK and 
8.6 ± 0.3% NK in CsA-MP group P < 0.05 for both com­
parisons). In addition, in NK and TK of rats treated with 
SRL a significant increase in palmitic (16:0) acid was 
shown (mean ± SEM were 18.7 ± 0.2% in control group 
vs. 20.8 ± 0.5% NK in SRL group and 20.7 ± 0.4% TK in 
SRL group P < 0.05 for both comparisons). Both treat­
ments produced a decrease in the n-6 fatty acid family 
(52 n-6 CsA-MP group: control 47.8, NK: 43.7 and TK: 
43.0; SRL group, control: 46.3, NK: 43.3 and TK: 42.4) as 
well as in the unsaturation index (calculated as 52 nixi/ 
FA where «j is the number of double bonds in each fatty 
acid; x1; moles of each fatty acid; FA, total moles of fatty 
acids) (CsA-MP group, control: 1.87, NK: 1.86 and TK: 
1.82; SRL group, control: 1.88, NK: 1.79 and TK: 1.78). 
An increase in n-3 fatty acids was observed in kidneys 
obtained from the CsA-MP-treated rats (52 n-3 CsA-MP 
group: control 2.7, NK: 4.9 and TK: 4.7).
The relative amount of the different lipid species in kid­
ney microsomal membranes of control and recipient rats 
is shown in Table 2. A significant increase in phospholipid 
levels and a decrease in cholesterol and in free fatty acids 
were found for both treatments. In SRL group a reduction 
of triglyceride values was also noted in the graft.
Table 3 shows the fatty acid composition of liver 
microsomal membranes. The main change observed in 
these membranes obtained from the rats treated with the 
immunosuppressants was a decrease in linoleic acid (18:2 
n-6) (15% decrease in CsA-MP group and 24% in SRL
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Table 2. Relative percentages of the lipid species in kidney microsomal membranes.
CONTROL
TXR CsA/MP SRL
NK TK NK TK NK TK
TG 3.2 ± 0.3 3.6 ± 0.3 4.3 ± 0.2 3.0 ± 0.3% 3.6 ± 0.6 2.1 ± 0.4% 1.5 ± 0.1%
FFA 5.0 ± 0.4 4.4 ± 0.4 4.8 ± 0.2 1.5 ± 0.2% 2.0 ± 0.4% 1.6 ± 0.1% 1.0 ± 0.2%
C 26.4 ± 1.2 23.5 ± 1.5 26.0 ± 0.9 14.5 ± 0.6% 17.3 ± 1.6% 15.6 ± 1.0% 14.8 ± 0.9%
PL 65.4 ± 1.4 67.8 ± 1.7 64.9 ± 1.0 81.0 ± 0.4% 77.1 ± 1.3% 80.3 ± 1.4% 83.3 ±1.1%
NK, native kidney; TK, transplanted kidney; TG, triglycerides; FFA, free fatty acids; C, cholesterol; PL, phospholipids.
Data are the mean of six determinations ±SEM expressed as relative mg% of total lipid species.
^Significantly different from pretransplant values at P < 0.05.
fSignificantly different from transplanted rats without immunosuppressive therapy at P < 0.05 using anova.
Table 3. Fatty acid composition of 
Fatty acid Control___________ TXR________________CsA/MP_____________ SRL total lipids of liver microsomes.
16:0 16.2 ± 0.3 17.4 ± 0.2 12.8 ± 1.2* 17.4 ± 0.4
16:1 0.3 ± 0.05 0.3 ± 0.02 0.2 ± 0.03 0.5 ± 0.05*
18:0 24.7 ± 0.6 25.2 ± 0.4 25.3 ± 0.4 25.4 ± 0.5
18:1 n-9 4.2 ± 0.3 4.0 ± 0.3 4.1 ± 0.1 5.6 ± 0.4*
18:1 n-7 1.0 ± 0.04 1.1 ± 0.1 1.5 ± 0.06 1.5 ± 0.2
18:2 n-6 17.7 ± 0.6 15.3 ± 0.4* 15.1 ± 0.6* 13.5 ± 0.8*
20:3 n-6 0.3 ± 0.04 0.3 ± 0.05 0.4 ± 0.05 0.7 ± 0.08*
20:4 n-6 27.5 ± 0.3 27.9 ± 0.3 29.3 ± 0.9 25.5 ± 0.9
22:4 n-6 0.4 ± 0.03 0.5 ± 0.02* 0.3 ± 0.03 0.4 ± 0.03
22:5 n-6 0.1 ± 0.05 0.3 ± 0.03 1.3 ± 0.1% 0.4 ± 0.03%
22:5 n-3 1.3 ± 0.1 1.0 ± 0.1 0.4 ± 0.02% 0.9 ± 0.07%
22:6 n-3 6.4 ± 0.2 6.7 ± 0.3 9.4 ± 0.5% 8.2 ± 0.4%
Fatty acids are identified by: number of carbon atoms in the chain is given first, value following the 
double point represents number of double bonds (zero means saturated fatty acids); number fol­
lowing 'n' indicates the position of the last double bond counting the double bond from the ter­
minal methyl group.
Data are the mean of six determinations ±SEM expressed as % of total fatty acids.
*Significantly different from control at P < 0.05.
fSignificantly different from transplanted rats without immunosuppressive therapy at P < 0.05 using 
ANOVA.
group), compared with controls. In the CsA-MP group a 
decrease in palmitic (16:0) and 22:5 n-3 together with an 
increase of 22:5 n-6 and 22:6 n-3 was observed compared 
with the control and nontreated recipient rats. In the SRL 
group an increase in 16:1 and 18:1 n-9 was observed.
Fig. 3 shows the fatty acid composition of testis micro­
somes. In the treated groups a significant decrease of pal­
mitoleic (16:1) acid was found compared with controls. 
In this tissue the decrease of 18:2 n-6 acid was 32% in 
CsA-MP and 28% in SRL group. In the CsA-MP group 
an increase of arachidonic, 20:3 n-6 and 22:5 n-6 acids, as 
well as a decrease of palmitic acid, were observed com­
pared with the remaining groups.
The most important change in erythrocyte membranes 
was the decrease in linoleic acid which was about 12%, 
either in the rats treated with CsA-MP or with SRL 
(mean ± SEM were 11.7 ± 0.1% in control group vs. 
10.6 ± 0.2% in CsA-MP group and 10.0 ± 0.4% in SRL 
group, P < 0.01 for both comparisons). There were no 
differences in plasma fatty acid composition of trans­
planted rats treated with either CsA-MP or SRL, com­
pared with the controls (data not shown).
Histopathology
The histopathologic study of nontreated transplanted kid­
neys revealed a moderate to severe degree of rejection, 
presenting at interstitial level dense inflammatory infil­
trates which developed to mononuclear predominance, 
hemorrhage and slight to moderate edema. Glomerules 
were observed with moderate vasocongestion and hyper - 
cellularity. Moderate tubulitis, focal tubular necrosis, 
moderate hyalinization and intimal vascular thickening of 
arteries and arterioles were also evident. CsA-MP therapy 
provoked a decrease in the interstitial, tubular and vascu­
lar abnormalities compared with the nontreated group. In
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Figure 3 Fatty acid composition of testis 
microsomal total lipids in control and 
transplanted rats. Identification of fatty 
acids as in Fig. 1. Data are the mean of 
six determinations ±SEM expressed as % 
of total fatty acids. * Significantly different 
from control at P < 0.05. §Significantly 
different from transplanted rats without 
immunosuppressive therapy at P < 0.05 
using anova.
addition, a slight to moderate proliferation of the glomer­
ular capsular epithelium was observed. SRL therapy mark­
edly improved morphological alterations, evidencing only 
a moderate focal leukocyte infiltration of perivascular 
preferential location with preservation of vascular and 
glomerular structures.
Discussion
Adverse effects on serum lipids have been reported con­
cerning the immunosuppressive therapy in transplanted 
patients as well as in experimental models of organ trans­
plantation [27]. The type and level of immunosuppressive 
agents used can also adversely produce post-transplant 
hyperlipidemia. However, in a previous study we observed 
50% increment in plasma cholesterol levels as well as modi­
fications in the lipid profile of kidney, testis and erythrocyte 
membranes in transplanted rats without immunosuppres­
sive therapy [26]. In a previous study, where the effect of 
CsA and MP administered to normal nontransplanted rats 
could be evaluated independently, it was demonstrated that 
cholesterol values were significantly and substantially 
increased under the dual immunosuppressive therapy [18]. 
In the same report, CsA monotherapy decreased plasma tri­
glyceride levels, but it did not modify plasma cholesterol 
levels. However, the CsA monotherapy in nontransplanted 
patients produced an increase in total plasma cholesterol 
and low-density lipoprotein cholesterol [1,28,29]. In trans­
planted rats studied here the hypercholesterolemia 
obtained from CsA-MP group was higher than that from 
transplanted nontreated rats (Table 1); effect that could be 
ascribed mainly to corticoid therapy.
Cyclosporine has been also associated with high trigly­
ceride levels through the inhibition of lipoprotein lipase 
[1]. Triglyceride levels remained unaltered when the dual 
therapy CsA-MP was administered to normal nontrans­
planted rats (18). Similar results were obtained in this 
work in recipient rats treated with both drugs. When SRL 
was administered in combination with corticosteroids a 
significant increase in triglyceride levels was shown [30]. 
Moreover, the hypertriglyceridemia returns to its pre­
transplantation values after reduction or discount SRL 
[30]. The European Study comparing SRL and CsA triple 
therapy reported that SRL treatment caused a more fre­
quent and severe hypercholesterolemia and hypertriglycer­
idemia than those of CsA (44% vs. 51% and 51% vs. 
12%, respectively). In our transplanted rats, we found 
that the monotherapy with SRL produced a considerable 
elevation of triglyceride values without producing any 
change in cholesterol levels (Table 1). In contrast to the 
increase in cholesterol and triglyceride plasma levels pro­
duced by the administration of CsA and SRL, respectively, 
both lipids were considerably reduced in the graft and in 
native kidney membranes (Table 2). From these data 
along with the significant increase in membrane phos­
pholipids we can infer that kidney membranes tend to be 
more fluid when the rejection damage is attenuated by 
the immunosuppressive therapy.
Related to the fatty acid profile of kidney microsomes, 
the decrease of arachidonic acid observed in the graft of 
rats under the dual therapy could be ascribed to both, the 
production of metabolites of the cyclo-oxygenase and 
5-lipoxigenase pathways and the production of lipocortin 
induced by corticoids [1]. CsA nephrotoxicity is associ­
ated with specific alterations in renal arachidonic acid 
metabolism [31]; arachidonic acid metabolites are consid­
ered important mediators of renal dysfunction and acute 
rejection [1,32]. However, lipocortin directly inhibits the 
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activity of phospholipase A2 which catalyzes the release of 
arachidonic acid from membrane phospholipids. How­
ever, in the present work a similar fatty acid profile of 
kidney microsomes was demonstrated with SRL which 
inhibits cytokine receptor-mediated signal transduction 
(20). The decrease in arachidonic acid was partially com­
pensated by an enhancement of the fatty acids of 22 C 
belonging to n-3 series in the CsA group. In the fatty acid 
pattern of liver and testicular microsomes as well as in 
erythrocyte membranes, the depression in the relative 
concentration of linoleic acid was the most important 
change in treated-transplanted rats. This fact together 
with minor changes in other PUFA led to a depression in 
the total amount of n-6 fatty acids in SRL group in liver 
microsome membranes. This effect was not evident in 
CsA-MP group. Then, an increase in the 22:6 n-3 was 
observed. Steroid therapy produced a significant decrease 
in the desaturation and thioesterification of linoleic acid 
in liver as shown elsewhere [18]. From the analysis of the 
fatty acid pattern in liver of rats treated with both immu­
nosuppressive drugs, we cannot infer the aforementioned 
effect. The relative percentages of PUFA belonging to 
linoleic acid remained similar to those of controls in spite 
of the depression observed in linoleic acid. A similar fatty 
acid pattern in nontreated transplanted rats has been 
published [26]. However, the enhancement observed in 
16:1/16:0 and 18:1/18:0 ratio in SRL group is an indirect 
evidence of the increment in A9 desaturation activity.
In conclusion, CsA-MP produced an additional incre­
ment in total cholesterol plasma levels when compared 
with those obtained in nontreated transplanted rats. The 
immunosuppressants improved the relative composition 
of the lipid species in kidney microsomes increasing 
phospholipids and decreasing cholesterol and triglycer­
ides. SRL deteriorates triglyceride plasma composition 
which showed 67% increase over the controls. However, 
this effect was not detected in kidney membranes where 
triglyceride and cholesterol levels were reduced compared 
with control kidneys. The fatty acid profile of the differ­
ent tissues in transplanted rats treated with either CsA- 
MP or SRL was not different from that occurring in 
nontreated transplanted rats [26]. Moreover, both treat­
ments improved the rejection of the graft evident through 
plasma creatinine levels and histopathological studies. 
This fact was remarkable in SRL-treated group. Currently, 
we are studying the effect of the immunosuppressive 
drugs at longer periods.
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